COMMUNIQUÉS West-GlobeNewswire

Novartis agrees to acquire Excellergy, Inc., building on allergy leadership with next-generation anti-IgE innovation
27/03/2026
- Proposed acquisition strengthens Novartis immunology strategy in food allergy and other IgE-driven diseases - Lead asset Exl-111 builds on proven IgE biology with a differentiated mechanism designed to dissociate [...]
UCB - Convocation à l'assemblée générale des actionnaires 2026
27/03/2026
CONVOCATION A L’ASSEMBLEE GENERALE DES ACTIONNAIRES Le Conseil d’administration invite les actionnaires à l’assemblée générale des actionnaires (« l’Assemblée Générale ») qui se tiendra le jeudi 30 avril 2026 à 11 [...]
Bavarian Nordic Submits Data to EMA to Extend Mpox and Smallpox Vaccine Approval to Children Aged 2-11 Years
27/03/2026
Submission based on topline data from clinical study, demonstrating a comparable safety profile and a non-inferior immune response for MVA-BN in children aged 2-11 years compared to adults. COPENHAGEN, Denmark, March 27 [...]
Zenas BioPharma Announces Pricing of Concurrent Public Offerings of 2.50% Convertible Senior Notes Due 2032 and Common Stock with Aggregate Gross Proceeds of $300.0 Million
27/03/2026
WALTHAM, Mass., March 27, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas,” “Zenas BioPharma” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the [...]
MEDVi Claims Evaluated: Most Affordable Tirzepatide GLP-1 Weight Loss Clinic Online — 2026 Search Trends and Publicly Available Pricing Information Context
27/03/2026
A 2026 informational overview of publicly available MEDVi tirzepatide GLP-1 pricing details, compounded medication access pathways, program structure, and regulatory context relevant to consumers researching affordable [...]
Gelatine Sculpt Claims Evaluated: Documenting the Gelatin Trick Recipe Investigation for Consumer Safety
27/03/2026
A 2026 consumer transparency report addressing Gelatine Sculpt's "bariatric jelly" terminology, gelatin trick recipe marketing references, GLP-1-related positioning, ingredient disclosure, proprietary blend context, and [...]
Radiant Health Centers Names Mark Gonzales Interim CEO Amid Period of Expansion
27/03/2026
Veteran Leader with 15+ Years of Service to Guide Growth, Increase Access to Care, and Deepen Community Impact Irvine, CA, March 26, 2026 (GLOBE NEWSWIRE) -- Radiant Health Centers today announced the appointment of [...]
Novo Nordisk A/S: Awiqli® approved in the US, the first and only once-weekly basal insulin treatment for adults with type 2 diabetes
27/03/2026
Awiqli ® (insulin icodec-abae) injection is the first-ever once-weekly basal insulin approved by the FDA Awiqli ® offers adults with type 2 diabetes an alternative to daily basal insulin injections, reducing these [...]
Beyond Air, Inc. Announces Resignation of Steve Lisi, CEO, and Appointment of Robert Goodman, Chief Commercial Officer, as CEO
26/03/2026
New Leadership to Accelerate Market Adoption and Scale Commercial Growth GARDEN CITY, N.Y., March 26, 2026 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical [...]
Kyverna Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results
26/03/2026
Advancing first-to-market autoimmune CAR T opportunity in stiff person syndrome (SPS) with key launch preparation activities underway; BLA submission anticipated in 1H 2026 Progressing enrollment for FDA-aligned Phase 3 [...]
Daré Bioscience Reports Full Year 2025 Financial Results and Provides Business Update
26/03/2026
Company Highlights Commercial Launch of DARE to PLAY™ Sildenafil Cream, Pipeline of Women's Health Solutions, and Multiple Near-Term Potential Catalysts Conference Call and Webcast Today at 4:30 p.m. ET SAN DIEGO, March [...]
Zenas BioPharma Announces Proposed Concurrent Public Offerings of Convertible Senior Notes Due 2032 and Common Stock
26/03/2026
WALTHAM, Mass., March 26, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas,” “Zenas BioPharma” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the [...]
SIGA Declares Special Cash Dividend of $0.60 Per Share
26/03/2026
NEW YORK, March 26, 2026 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (Nasdaq: SIGA), a commercial-stage pharmaceutical company, today announced that its board of directors declared a special cash dividend of $0. [...]
Galapagos Announces Nomination of Gino Santini to its Board of Directors
26/03/2026
Subject to his election by shareholders, the Board intends to appoint Mr. Santini as Chair, succeeding Jérôme Contamine Mr. Santini will bring extensive corporate governance, business development and industry leadership [...]
Rani Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results; Provides Corporate Update
26/03/2026
- Announced up to $1.085 billion collaboration with Chugai Pharmaceutical Co. for multiple high-value therapeutics and completed $60.3 million oversubscribed private placement led by Samsara BioCapital with [...]
NurExone Strengthens U.S. Manufacturing Strategy Through Exo-Top Sublicense Agreement
26/03/2026
Exo-Top Inc. positioned as a strategic U.S. subsidiary supporting manufacturing, clinical advancement and long-term value creation TORONTO and HAIFA, Israel, March 26, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. ( [...]
Galapagos Publishes 2025 Annual Report and Announces Annual and Extraordinary Shareholders’ Meetings
26/03/2026
Mechelen, Belgium; March 26, 2026, 21:01 CET; regulated information — Galapagos NV (Euronext & NASDAQ: GLPG) today published its annual report for the financial year 2025 and announced that its Annual Shareholders’ [...]
Precision Optics Corporation, Inc. Announces Proposed Public Offering of Common Stock
26/03/2026
GARDNER, Mass., March 26, 2026 (GLOBE NEWSWIRE) -- Precision Optics Corporation, Inc. (NASDAQ: POCI), a leading designer and manufacturer of advanced optical instruments for the medical and defense/aerospace industries [...]
Inhibikase Therapeutics Announces Full Year 2025 Financial Results and Highlights Recent Activity
26/03/2026
WILMINGTON, Del., March 26, 2026 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing therapeutics to modify the course of [...]

Pages